课题基金 / 基金详情

Bioanalytical Core

Bioanalytical Core
生物分析核心
批准号:
10374823
负责人:
Matthew Sean Halquist
金额:
$25.63万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-12-01 至 2024-03-31

项目摘要

项目成果

Matthew Sean Halquist的其他基金

相关文献

中文摘要
翻译
项目总结-生物分析核心 生物分析核心实验室将提供最先进和创新的生物分析专业知识, 药物及其代谢物、内源性化学物质和其他药物分子的定量技术 与中心其他核心和所有资助药物的新合作研究中的生物学意义 在这所大学和邻近的大学里虐待生物医学研究人员。这些分析将提供专门知识, 进行新的和创新的研究,并以意想不到的方式加强目前资助的研究项目 在提交申请时。该核心将通过提供可靠的, 生物和非生物材料的有效质谱分析,用于新项目以及 美国国立卫生研究院赞助和其他研究人员研究滥用物质和成瘾的作用机制。 该实验室将开发专注于识别和定量生物标本的方法, 药物和/或药物代谢物,如可卡因、尼古丁、可替宁、四氢大麻酚(THC),和天然的 存在的精神活性化合物如荷叶碱、阿扑吗啡和米曲宁,以及生理活性化合物, 活性内源性小分子和/或其代谢物如大麻素,其它内源性大麻素, 前列腺酰胺和神经酰胺的鞘磷脂代谢物。这些分析将加强 通过提供包括药物处置在内的药代动力学分析,对滥用药物进行药理学研究, 代谢和清除。生物分析核心将开发新颖和创新的技术, 快速分离和定量极性药物代谢物和葡糖苷酸的样品制备 代谢物。我们将扩大小分子类型的广度,包括其他滥用物质 特制药物(即,合成阿片类药物、大麻拟似物和卡西酮)及其代谢物, 与滥用药物具有相似药理作用的内源性化合物,包括 内源性大麻素、肽、脂质和其它生物递质或信号化合物。我们还将 通过差分离子迁移率质谱(DMS)增强选择性能力, 我们的同量异位化合物的定量,识别以前没有见过的代谢物,以及分离感兴趣的离子, 干扰离子。微萃取/样品制备技术和/或二维 色谱分离结合质谱(MS),DMS选择性能力,将提供 新的层面的研究提出的所有药物滥用研究人员在这个校园和那些在我们的 邻近的机构。
英文摘要
Project Summary – Bioanalytical Core The Bioanalytical Core Laboratory will provide state of the art and innovative bioanalytical expertise and techniques for the quantification of drugs and their metabolites, endogenous chemicals and other molecules of biological significance in new collaborative studies with the other cores in the center and all the funded drug abuse biomedical researchers at this and neighboring universities. These analyses will provide the expertise to perform new and innovative research and to enhance currently funded research projects in ways not anticipated at the time of their application submission. This core will accomplish these goals by making available reliable, validated mass spectrometric analysis of biological and non-biological materials for new projects as well as for NIH sponsored and other researchers studying the mechanism of action of abused substances and addiction. The laboratory will develop methods focused on the identification and quantification in biologic specimens of drugs and/or drug metabolites, such as cocaine, nicotine, cotinine, tetrahydrocannabinol (THC), and, natural occurring psychoactive compounds such as nuciferine, apomorphine and mitragynine, as well as physiologically active small endogenous molecules and/or their metabolites such as anandamide, other endocannabinoids, prostamides and ceramide metabolites of sphingomelingolipids. These analyses will enhance the pharmacological studies of drugs of abuse by providing pharmacokinetic analysis including drug disposition, metabolism and clearance. The Bioanalytical Core will develop novel and innovative techniques for minimum sample preparation to allow rapid isolation and quantification of polar drug metabolites and glucuronide metabolites. We will expand on the breadth of types of small molecules including additional substances of abuse designer drugs (i.e., synthetic opioids, cannabimimetic, and cathinones), and their metabolites, a wider range of endogenous compounds which have similar pharmacological effects as drugs of abuse including endocannabinoids, peptides, lipids and other biological transmitters or signaling compounds. We will also enhance selectivity capabilities with differential ion mobility mass spectrometry (DMS) allowing us to increase our quantification of isobaric compounds, identify metabolites not seen before, and separation of ions of interest from interfering ions. Incorporating micro-extraction/sample preparation technologies and/or two-dimensional chromatographic separations combined with mass spectrometry (MS), DMS selectivity capability, will provide new dimensions to the research proposed of all drug abuse researchers on this campus and those in our neighboring institutions.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bioanalytical Core
  • 批准号:
    10604266
  • 项目类别:
  • 资助金额:
    $25.63万
  • 财政年份:
    2013
  • 负责人:
    Matthew Sean Halquist
  • 依托单位: